Establishment of QED Therapeutics

Goodwin advised BridgeBio Pharma on the transaction

BridgeBio Pharma as launched a new subsidiary, QED Therapeutics, to drive the development of infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, which has been implicated as a driver mutation across multiple forms of cancer. Infigratinib is licensed to QED from Novartis, and BridgeBio has made an initial financial commitment of $65 million, inclusive of an upfront payment to Novartis as well as an equity investment in QED.

BridgeBio, led by is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source. Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of fifteen transformative assets, each housed in its own subsidiary, ranging from pre-clinical to late stage development in multiple therapeutic areas including oncology, cardiology, neurology, dermatology and endocrinology. The company’s focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines.

The Goodwin team was led by partner Maggie Wong (Picture) and associate Noelle Dubiansky and included partner Theresa Kavanaugh; and associates Emily Beman, Aaron Chan, Derek Denhart and Rahul Magan.

Involved fees earner: Maggie Wong – Goodwin Procter; Emily Beman – Goodwin Procter; Aaron Chan – Goodwin Procter; Rahul Magan – Goodwin Procter; Noelle Dubiansky – Goodwin Procter; Theresa Kavanaugh – Goodwin Procter; Derek Denhart – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: BridgeBio Pharma LLC;

Print Friendly, PDF & Email

Author: Ambrogio Visconti